S&P 500   3,913.95 (-0.25%)
DOW   31,319.54 (-0.54%)
QQQ   291.21 (+0.02%)
AAPL   137.56 (-2.32%)
MSFT   253.71 (-0.15%)
FB   192.72 (+0.25%)
GOOGL   2,212.80 (-1.13%)
AMZN   2,165.00 (+1.06%)
TSLA   715.18 (+0.76%)
NVDA   173.97 (+2.71%)
BABA   88.23 (+1.05%)
NIO   16.76 (+5.87%)
AMD   98.53 (+2.34%)
CGC   5.96 (+6.62%)
MU   70.29 (-1.07%)
T   20.17 (-0.30%)
GE   75.79 (+0.78%)
F   13.00 (+1.72%)
DIS   103.73 (-0.55%)
AMC   12.95 (+1.49%)
PFE   50.44 (+0.08%)
PYPL   81.64 (+5.78%)
NFLX   185.44 (+4.66%)
S&P 500   3,913.95 (-0.25%)
DOW   31,319.54 (-0.54%)
QQQ   291.21 (+0.02%)
AAPL   137.56 (-2.32%)
MSFT   253.71 (-0.15%)
FB   192.72 (+0.25%)
GOOGL   2,212.80 (-1.13%)
AMZN   2,165.00 (+1.06%)
TSLA   715.18 (+0.76%)
NVDA   173.97 (+2.71%)
BABA   88.23 (+1.05%)
NIO   16.76 (+5.87%)
AMD   98.53 (+2.34%)
CGC   5.96 (+6.62%)
MU   70.29 (-1.07%)
T   20.17 (-0.30%)
GE   75.79 (+0.78%)
F   13.00 (+1.72%)
DIS   103.73 (-0.55%)
AMC   12.95 (+1.49%)
PFE   50.44 (+0.08%)
PYPL   81.64 (+5.78%)
NFLX   185.44 (+4.66%)
S&P 500   3,913.95 (-0.25%)
DOW   31,319.54 (-0.54%)
QQQ   291.21 (+0.02%)
AAPL   137.56 (-2.32%)
MSFT   253.71 (-0.15%)
FB   192.72 (+0.25%)
GOOGL   2,212.80 (-1.13%)
AMZN   2,165.00 (+1.06%)
TSLA   715.18 (+0.76%)
NVDA   173.97 (+2.71%)
BABA   88.23 (+1.05%)
NIO   16.76 (+5.87%)
AMD   98.53 (+2.34%)
CGC   5.96 (+6.62%)
MU   70.29 (-1.07%)
T   20.17 (-0.30%)
GE   75.79 (+0.78%)
F   13.00 (+1.72%)
DIS   103.73 (-0.55%)
AMC   12.95 (+1.49%)
PFE   50.44 (+0.08%)
PYPL   81.64 (+5.78%)
NFLX   185.44 (+4.66%)
S&P 500   3,913.95 (-0.25%)
DOW   31,319.54 (-0.54%)
QQQ   291.21 (+0.02%)
AAPL   137.56 (-2.32%)
MSFT   253.71 (-0.15%)
FB   192.72 (+0.25%)
GOOGL   2,212.80 (-1.13%)
AMZN   2,165.00 (+1.06%)
TSLA   715.18 (+0.76%)
NVDA   173.97 (+2.71%)
BABA   88.23 (+1.05%)
NIO   16.76 (+5.87%)
AMD   98.53 (+2.34%)
CGC   5.96 (+6.62%)
MU   70.29 (-1.07%)
T   20.17 (-0.30%)
GE   75.79 (+0.78%)
F   13.00 (+1.72%)
DIS   103.73 (-0.55%)
AMC   12.95 (+1.49%)
PFE   50.44 (+0.08%)
PYPL   81.64 (+5.78%)
NFLX   185.44 (+4.66%)
NASDAQ:SUPN

Supernus Pharmaceuticals (SUPN) Stock Forecast, Price & News

$27.38
+0.43 (+1.60%)
(As of 05/19/2022 02:06 PM ET)
Add
Compare
Today's Range
$26.75
$27.41
50-Day Range
$25.33
$34.25
52-Week Range
$23.15
$34.50
Volume
23,189 shs
Average Volume
510,593 shs
Market Capitalization
$1.46 billion
P/E Ratio
21.06
Dividend Yield
N/A
Beta
1.12
30 days | 90 days | 365 days | Advanced Chart
Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Supernus Pharmaceuticals logo

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:SUPN
CUSIP
86845910
Employees
575
Year Founded
N/A

Sales & Book Value

Annual Sales
$579.78 million
Cash Flow
$1.96 per share
Book Value
$15.51 per share

Profitability

Net Income
$53.42 million
Pretax Margin
12.80%

Debt

Price-To-Earnings

Miscellaneous

Free Float
49,145,000
Market Cap
$1.46 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/09/2022
Today
5/19/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

918th out of 1,418 stocks

Pharmaceutical Preparations Industry

459th out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

Is Supernus Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Supernus Pharmaceuticals stock.
View analyst ratings for Supernus Pharmaceuticals
or view top-rated stocks.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Supernus Pharmaceuticals
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted its earnings results on Monday, May, 9th. The specialty pharmaceutical company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.26 by $0.17. The specialty pharmaceutical company had revenue of $152.50 million for the quarter, compared to analysts' expectations of $150.47 million. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 9.05% and a net margin of 12.20%. The firm's quarterly revenue was up 16.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.11 EPS.
View Supernus Pharmaceuticals' earnings history
.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $640.00 million-$680.00 million, compared to the consensus revenue estimate of $683.81 million.

What price target have analysts set for SUPN?

1 brokers have issued 1 year price targets for Supernus Pharmaceuticals' shares. Their forecasts range from $44.00 to $44.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $44.00 in the next twelve months. This suggests a possible upside of 61.4% from the stock's current price.
View analysts' price targets for Supernus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Supernus Pharmaceuticals' key executives?
Supernus Pharmaceuticals' management team includes the following people:
  • Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 61, Pay $1.68M)
  • Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 65, Pay $582.2k)
  • Ms. Tami T. Martin, Sr. VP of Regulatory Affairs (Age 67, Pay $495.2k)
  • Mr. Timothy C. Dec, Sr. VP & CFO (Age 63)
  • Mr. Kevin T. Anderson, Compliance Officer (Age 60)
  • Dr. Todd Horich M.B.A., Ph.D., Sr. VP of Marketing & Market Access
  • Mr. Taylor Raiford, Sr. VP of Sales
  • Dr. Bryan A. Roecklein Ph.D., Sr. VP of Corp. Devel.
  • Mr. Frank Mottola, Sr. VP of Quality, GMP Operations & Information Technology (Age 50)
  • Mr. Jeff Bozick, Sr. VP of Supply Chain
What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals CEO Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among Supernus Pharmaceuticals' employees.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.37%), Dimensional Fund Advisors LP (4.16%), GW&K Investment Management LLC (3.42%), Loomis Sayles & Co. L P (3.05%), Stephens Investment Management Group LLC (3.00%) and Renaissance Technologies LLC (2.33%). Company insiders that own Supernus Pharmaceuticals stock include Frederick M Hudson, Gregory S Patrick, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends for Supernus Pharmaceuticals
.

Which major investors are selling Supernus Pharmaceuticals stock?

SUPN stock was sold by a variety of institutional investors in the last quarter, including Polar Capital Holdings Plc, Royce & Associates LP, Bruce & Co. Inc., Mondrian Investment Partners LTD, Lisanti Capital Growth LLC, Bridge City Capital LLC, Loomis Sayles & Co. L P, and Exchange Traded Concepts LLC.
View insider buying and selling activity for Supernus Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Supernus Pharmaceuticals stock?

SUPN stock was acquired by a variety of institutional investors in the last quarter, including Woodline Partners LP, Goldman Sachs Group Inc., Congress Asset Management Co. MA, Bellevue Group AG, Walleye Capital LLC, Frontier Capital Management Co. LLC, Charles Schwab Investment Management Inc., and Vanguard Group Inc..
View insider buying and selling activity for Supernus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $27.26.

How much money does Supernus Pharmaceuticals make?

Supernus Pharmaceuticals has a market capitalization of $1.46 billion and generates $579.78 million in revenue each year. The specialty pharmaceutical company earns $53.42 million in net income (profit) each year or $1.299990 on an earnings per share basis.

How many employees does Supernus Pharmaceuticals have?

Supernus Pharmaceuticals employs 575 workers across the globe.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is www.supernus.com.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at (301) 838-2500, via email at [email protected], or via fax at 301-838-2501.

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.